Abbott Sues India’s Lupin Over Cholesterol Generic
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Abbott Laboratories has filed a suit to stop India's Lupin from selling a generic of Abbott's cholesterol drug Niaspan (niacin). Abbott said in its suit it has seven U.S. patents on the drug, the earliest not set to expire until 2013. The American company, which acquired the drug when it bought Kos Pharmaceuticals in 2006, filed the patent suit in two separate federal courts. (Click here for more